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Globalization of Clinical Trials
How Should We Interpret
Differences in Outcomes?*
Barry M. Massie, MD
San Francisco, California
Over the last 3 decades, clinical trials have become increas-
ingly globalized. This has especially been the case for
cardiovascular outcomes trials. There are many reasons for
this phenomenon, but foremost is the growing size and
length of clinical heart failure trials. For example, the
modern era of heart failure therapy with neurohormonal
antagonists was ushered in by the Captopril Multicenter
Trial published in 1983, in which 92 patients with refractory
heart failure were randomized to captopril or placebo with a
primary endpoint of improvement in treadmill exercise time
after 3 months of treatment (1). Surprisingly, even with
this small number of patients, a subsequent post-hoc anal-
ysis showed a significantly lower mortality rate in the
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captopril group compared with the placebo group (4% vs.
21%) (2). The captopril trial was followed by the 253-
patient CONSENSUS I (Cooperative North Scandinavian
Enalapril Survival Study) (3), which was stopped in 1986 by
its safety monitoring committee after a mean follow-up
period of 188 days, at which point, 66 patients in the
placebo group and 44 patients in the enalapril group had
died, representing a 40% reduction in mortality. Impor-
tantly, these trials, which were small and short in length, led
to approval of the study drugs for the treatment of heart
failure.
However, as time has passed, heart failure trials have
become increasingly large, to the point that many are now
deservedly termed “megatrials,” with most recent Phase 3
heart failure trials enrolling several thousand patients. The
major reasons for this are listed in Table 1. Serial advances
in therapy with drugs and, more recently, devices have
improved the prognosis of heart failure patients, prevented
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of life. Demonstrating meaningful benefit with an addi-
tional agent on current guideline-recommended therapies
has become increasingly difficult. Mortality reductions rarely
approach the 20% to 30% range over a 1- to 3-year period,
necessitating larger and longer trials that can detect much
more modest, albeit clinically meaningful, improvements.
Given advances in therapy, it has become increasing difficult
to include placebo groups, so often an active comparator
with known efficacy is utilized, making it more difficult to
show an incremental benefit. Alternatively, a noninferiority
design may be utilized to ensure that the new therapy is at
least as good as another therapy with proven efficacy. This
type of trial requires even larger numbers of patients
depending on the noninferiority margin selected. With the
current focus on drug safety, even larger trials may be
required to exclude unexpected safety problems when a
novel agent is studied.
All of these factors have led to ever-larger trials. At the
same time, driven by the growing administrative and regu-
latory burdens, the costs of clinical trials, both at the site
level and to the sponsors, have grown even faster than the
size of the trials. This is particularly the case in the United
States. As a result, major trials have become increasingly
international, often employing large numbers of sites in
multiple countries and continents. Many now involve not
only North America and Western Europe, but also coun-
tries in Eastern Europe, Latin America, and both East and
South Asia. Patients enrolled in the United States typically
represent a minority of the study population. However, this
globalization ensures a very heterogeneous study population,
with potential major differences in genetics, environmental
factors, diet, behaviors, comorbid conditions, concomitant
medications, utilization of invasive procedures and devices,
and other practice patterns (4–6). For instance, average
lengths of stay for a patient with heart failure vary from as
low as 4 to 5 days in the United States, to 2 to 3 weeks in
Russia, resulting in a greater impact on readmission rates,
which are frequently a component of the primary endpoint
in heart failure trials.
It is in this context of globalization and practice variation
that the paper by O’Connor et al. (7) in this issue of the
Journal assumes considerable importance. Their report spe-
cifically examines many of the major beta-blocker heart
failure trials. Two of these trials enrolled patients in both
the United States and outside North America. MERIT-HF
(Metoprolol Controlled-Release Randomized Intervention
Trial in Heart Failure) enrolled 3,991 patients with New
York Heart Association functional class II to IV heart
failure and ejection fraction 0.40 (mean ejection fraction:
0.28; 1,071 in the United States) who were randomized to
metoprolol succinate, a 1-selective agent, or placebo (8).
The COPERNICUS (Carvedilol Prospective Randomized
Cumulative Survival) trial studied 2,249 patients with severe
systolic heart failure (mean ejection fraction: 0.20; 482 in
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Globalization of Clinical Trials August 23, 2011:923–4the United States) who were randomized to carvedilol, a
nonselective 1/2-blocker with some -blocking activity,
r placebo (9). BEST (Beta-Blocker Evaluation of Survival
rial) was conducted entirely in North America. It enrolled
,708 patients with New York Heart Association functional
lass III or IV heart failure and ejection fraction 0.35
mean: 0.23; all 2,708 from the United States or Canada)
ho were randomized to bucindolol, a nonselective beta-
locker with possible intrinsic sympathomimetic activity
10,11). The results of the CIBIS II (Cardiac Insufficiency
isoprolol Study II) trial (12), which studied bisoprolol, a
1-selective agent, were also included in this analysis, but
since none of the patients were enrolled in North America,
its results will not be discussed in this commentary.
The provocative major finding of the O’Connor et al. (7)
analysis is that there appears to be a lesser survival benefit of
each of the 3 beta-blockers that were studied in North
American patients than in patients enrolled in the rest of the
world. However, 81% (841 of 1,035) of the North American
deaths occurred in the BEST, with only 194 occurring in
MERIT and COPERNICUS combined. The deaths in the
latter 2 trials are evenly split, with wide confidence intervals
that do not exclude a meaningful mortality benefit of 20%
in the U.S. patients.
The analyses in the O’Connor et al. (7) paper are
provocative and possibly hypothesis generating, but they
should not be interpreted as demonstrating a lesser beta-
blocker benefit in North American patients, given the wide
confidence intervals, particularly in COPERNICUS and
MERIT-HF. Subsequent experience has solidified the
powerful role that beta-blockers can play in preventing and
even reversing myocardial systolic dysfunction in heart
failure patients. Based on the totality of data with beta-
blockers and their experience, few heart failure physicians
would withhold carvedilol or metoprolol from their patients.
Nor should these findings be completely dismissed, but
alternative explanations must be considered. First, as noted
in the previous text, the finding of lesser benefit from
beta-blockers in North America is largely driven from the
BEST results and cannot be extrapolated with confidence to
easons for Globalization of Heart Failure TrialsTable 1 Reasons for Globalization of Heart Failure Trials
Increasing size of clinical trials
Improving background therapy
Declining outcome rates
Need to detect smaller effects
Lack of a placebo control group
Growing emphasis on safety
Declining enrollment rates in the United States and Western Europe
Increasing administrative burden
Higher costs
Expanding potential marketscarvedilol or metoprolol succinate, the beta-blockers com- mmonly used in the United States for heart failure patients,
because of the small numbers of events and wide confidence
around the effect estimates.
Lastly, there are important differences between BEST
and the other large beta-blocker trials that were conducted
in the United States. The BEST trial included a higher
proportion (23%) of African Americans, who more fre-
quently carry polymorphisms that are associated with a
lesser benefit from bucindolol (13). Other researchers have
reported that bucindolol has intrinsic sympathomimetic
activity, which may abrogate the benefit of beta-blocker
therapy (11). However, most important, one cannot exclude
the play of chance in these findings.
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